Background: The incidence and clinical characteristics of adverse pulmonary reactions resulting from anticancer monoclonal antibody (mAbs) therapy have not been well described. We determined the incidence and clinical characteristics of adverse pulmonary reactions in patients treated with anticancer chemotherapy including mAbs. Methods: A retrospective cohort study was performed including patients who were treated with a chemotherapeutic regimen that included rituximab, trastuzumab, cetuximab, or bevacizumab at Seoul National University Hospital between January 1, 2004 and December 31, 2008. Rates of adverse pulmonary reactions classified as non-infectious and infectious complications were compared with those among patients treated with comparable regimens without mAbs. Results: In total, 1078 patients were included (418 for rituximab, 329 for trastuzumab, 122 for cetuximab, 209 for bevacizumab). Adverse pulmonary reactions were identified in 36 patients (3.5%) and the incidence differed among agents: cetuximab (9%), rituximab (5.3%), trastuzumab (0.6%), bevacizumab (0.5%). Infectious pulmonary complications occurred in 28 patients, and eight patients experienced non-infectious pulmonary complications, most commonly interstitial lung disease (6 patients). In a multivariate analysis, low serum albumin level was associated with the development of pulmonary complications. The incidence of overall adverse pulmonary reactions did not differ between the mAbs users and the 1012 patients treated with comparable regimens other than mAbs (3.5% vs. 2.8%, P Z 0.53).
Introduction
New anti-neoplastic agents are constantly being added to the list of available treatments for various cancers. 1, 2 Among them, biological agents are one of the most promising modalities to combat cancers and other diseases. 3 In fact, more than 20% of the compounds approved by United States regulatory authorities over the last 5 years were biological agents. 4 Representative new anti-neoplastic biological agents are monoclonal antibodies (mAbs), which bind specifically to target cells. By blocking specific cell receptors, mAb therapy destroys malignant tumor cells and prevents tumor growth. 5 For example, rituximab, which targets the CD20 receptor, is widely used for CD20 þ non-Hodgkin's lymphoma (NHL). 6 Cetuximab, which binds to the epidermal growth factor receptor (EGFR), has shown efficacy in patients with colorectal, head/neck, and non-small cell lung cancers. 7 As with other anticancer drugs, adverse pulmonary events associated with mAbs can occur, including dyspnea, pulmonary embolism, pneumonia, interstitial lung disease, and pleural effusion. 6e11 In this study, we determined the incidence and clinical characteristics of adverse pulmonary drug reactions in patients treated with anticancer chemotherapy including mAbs in combination with other agents or as monotherapy.
Materials and methods

Study population
A retrospective cohort study was performed with patients who were treated with a chemotherapeutic regimen included rituximab, trastuzumab, cetuximab, or bevacizumab at Seoul National University Hospital between January 1, 2004 and December 31, 2008 . Patients, older than 18 years, who were being treated for their cancer with the aforementioned mAbs, were included. Patients lost to follow-up immediately after the first chemotherapy session were excluded. For comparison, patients treated with comparable regimens without mAbs were also included: CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone) users as counterparts of rituximab users, Taxol users as counterparts of trastuzumab users, and FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil) or FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil) users as counterparts of cetuximab and bevacizumab users. The Ethical Review Committee of our institution approved the protocol for this study.
Clinical data review
Patient clinical data, including medical records, radiographic findings, and laboratory results were reviewed.
Definition of adverse pulmonary reaction
New respiratory symptoms or abnormal radiographic/laboratory results that developed after mAb use were reviewed as possible adverse reactions. Two of the authors (HJ Kang and JS Park) reviewed the data independently. If their opinions on the presence of an adverse pulmonary reaction differed, another author (JJ Yim) made the decision. Adverse pulmonary reactions were divided into noninfectious and infectious complications, based on a previous study. 1 
Non-infectious complications
Infectious complications
Symptoms of an acute lower-respiratory tract illness (cough and at least one other lower-respiratory tract symptom).
-New focal chest signs on examination. 
Statistical analysis
The baseline characteristics of patients were expressed as median values with interquartile ranges (IQR) or means AE standard deviation (SD). Univariable analysis was performed to identify risk factors for pulmonary complication associated with anticancer chemotherapy including monoclonal antibodies. Between the groups with pulmonary adverse reaction group and the non-pulmonary complication group, comparisons of demographic characteristics, laboratory results, and treatment outcomes were performed using Pearson's c 2 test or Fisher's exact test for categorical variables and Student's t test for continuous variables. Multivariable analysis was performed using the logistic regression procedure to assess the relationship between several factors and the onset of pulmonary complication. P values less than 0.05 were considered statistically significant. All statistical analyses were performed with SPSS software (version 17.0, Chicago, IL, USA)
Results
Patient baseline characteristics
In total, 1078 patients were included in the analysis (418 for rituximab, 329 for trastuzumab, 122 for cetuximab, 209 for bevacizumab). Their median age was 54.3 (range, 18.2e91.1 years), and 39.2% were males. Rituximab was used only for patients with lymphoma, trastuzumab for those with breast cancer, cetuximab for colorectal and head and neck cancers, and bevacizumab for colorectal, breast, and head and neck cancers. In total, 184 (17.1%) patients received mAb chemotherapy as monotherapy ( Table 1) . As a comparison group, a total of 1012 patients treated during study period were included: 123 CHOP users, 119 Taxol users, and 770 FOLFOX or FOLFIRI users ( Table 1 ).
Incidence of pulmonary adverse reaction
Of the 1078 patients, adverse pulmonary reactions were identified in 36 (3.5%). The incidence differed among the agents: cetuximab (11/122, 9%), rituximab (22/418, 5.3%), trastuzumab (2/329, 0.6%), bevacizumab (1/209, 0.5%). Infectious pulmonary complications occurred in 28 patients, and eight patients experienced non-infectious pulmonary complications. Pneumonia developed in two out of three lung cancer patients on cetuximab. Six of these eight patients were diagnosed with interstitial lung disease and two with acute hypersensitivity and bronchospasm during infusion of mAbs. Interstitial lung disease was diagnosed through thoracoscopic surgical biopsy in one patient. Diffuse thickening and fibrosis of alveolar septal wall was the major pathologic finding. The other five patients were diagnosed based on clinical and radiographic findings. Dyspnea was the most common symptom and diffuse ground-glass opacities were observed most frequently on their computed tomography of the chest. The median number of cycles of mAb treatment prior to the adverse pulmonary reactions was three. The incidence of adverse pulmonary reactions in patients treated only with a mAb regimen did not differ from all patients (7/184, 3.8%; P Z 0.655) ( Table 2) . Among 1012 patient in the comparison groups, 28 (2.8%) patients experienced adverse pulmonary reactions. It was not different from that of 1078 patients (3.5%) treated with comparable regimens with monoclonal antibodies (P Z 0.53). However, incidence of adverse pulmonary reaction was higher among cetuximab users than counterpart group (9% vs. 1.7%, P < 0.001), mainly from higher rate of infectious complications ( Table 2 ).
Evolution of pulmonary adverse reaction
Ten of the 28 patients with pneumonia as a pulmonary adverse reaction from the mAbs improved with the use of antimicrobials. Despite meticulous use of wide-spectrum antibodies, pneumonia aggravation caused death in the other 18 patients. All eight patients with non-infectious adverse reactions improved. Four of them were administered 0.5e1 mg/kg/day methylprednisolone for several days.
Risk factors of pulmonary adverse reaction
Male gender and a history of smoking were more common in patients with adverse pulmonary reactions (Table 3) . However, only low serum albumin level was associated with the development of adverse pulmonary reactions after adjusting for other variables (odds ratio, 0.32; 95% confidence interval, 0.182e0.561). The fitness of this model was confirmed with the HosmereLemeshow goodness of fitness test (P Z 0.173; Table 4 ).
Discussion
Despite an explosion in the number of available moleculartargeted agents, limited data exists regarding adverse events associated with their use. 4 Drug-associated lung injury results either from cellular dysfunction, which induces apoptosis, or by impairing the cell and tissue repair sequence. 2 For example, EGFR is expressed on type II pneumocytes, which are involved in alveolar wall repair. Thus, agents targeting the EGFR, such as cetuximab, may impair alveolar repair mechanisms. 14, 15 Another process that is likely involved is angiogenesis, which plays a key role in wound healing. Mediators of wound angiogenesis, such as vascular endothelial growth factor (VEGF), have been identified in several wound healing models. Bevacizumab, which blocks the VEGF receptor, could inhibit the wound healing process during recovery from a lung injury. 16, 17 We identified 36 (3.5%) of the 1078 patients with cancer who developed adverse pulmonary reactions during or after treatment with a regimen that included mAbs. Pneumonia occurred in 28 patients, and eight patients experienced non-infectious pulmonary complications, most commonly, interstitial lung disease (6 patients).
The incidence of adverse pulmonary reactions in our patients was quite similar to that in previous studies. Previous studies reported that rituximab-induced interstitial lung disease (ILD) at <0.03%. 6, 8, 9 In our study, the incidence of rituximab-ILD was 1.4%. In our study, adverse pulmonary reactions were rare among patients treated with trastuzumab (0.6%) and it was similar to other studies (0.4e9.6%). 18e20 However, the incidence of adverse pulmonary reactions in cetuximab users in our study (9%) seemed to be higher than reported rates (3.4%) from cetuximab users with colorectal cancers. 7 In fact, the incidence of adverse pulmonary reaction was higher among cetuximab users than their counterpart group (9% vs. 1.7%, P < 0.001), in our study. The reason why cetuximab users in our cohort were more susceptible to adverse pulmonary reaction than others should be determined through future studies.
Low albumin level was identified as a risk factor for developing an adverse pulmonary reaction in this study. Low albumin level is a strong risk factor for patients who are admitted to the hospital with pneumonia after discharge. 21, 22 Poor nutritional status, as evidenced by low cholesterol, hypo-albuminemia, and low body weight due to chronic or severe malnutrition, is an important risk factor for pneumonia. 23 Because pneumonia was the most common adverse event in this study, a lower albumin level could be a risk factor for developing adverse pulmonary events.
In conclusion, infectious and non-infectious adverse pulmonary reactions occur in patients with cancer who are administered a regimen including monoclonal antibodies. Clinicians should be alert for the possibility of adverse pulmonary reactions, particularly among patients with a low serum albumin level. 
